Thomas Yau and colleagues’ CheckMate 9DW trial has yielded unprecedented results, with nivolumab plus ipilimumab reaching an overall response rate of 36%, a median progression-free survival of 9·1 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback